Watch for ICON to Potentially Pullback After Gaining 2.94% Yesterday
Comtex SmarTrend(R) - 57 mins ago
ICON (NASDAQ:ICLR) traded in a range yesterday that spanned from a low of $40.51 to a high of $42.10. Yesterday, the shares gained 2.9%, which took the trading range above the 3-day high of $41.00 on volume of 898,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Health Care Sector Equities Technical Data -- Research on Albany Molecular Research, Agilent Technologies, Thermo Fisher Scientific, and ICON
PR Newswire - Tue May 13, 8:15AM CDT
The U.S. markets on Monday, May 12, 2014 ended on a positive note as the Dow Jones Industrial Average finished at 16,695.47, up 0.68% and the NASDAQ Composite closed at 4,143.86, up 1.77%. The S&P 500 finished the session 0.97% higher at 1,896.65. During the trading session, eight out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 675.29, up 1.04%, with the index advancing 4.74% in the last one month. Investor-Edge has initiated coverage on the following equities: Albany Molecular Research Inc. (NASDAQ: AMRI), Agilent Technologies Inc. (NYSE: A), Thermo Fisher Scientific Inc. (NYSE: TMO) and ICON PLC (NASDAQ: ICLR). Free technical research on AMRI, A, TMO and ICLR can be downloaded upon signing up at:
Aptiv Solutions Improves Accuracy of Dose Escalation Studies with Launch of ADDPLAN(R) DF 3.0
PRWeb - Tue May 13, 6:12AM CDT
ICON plc (NASDAQ: ICLR), today announced that Aptiv Solutions, an ICON plc company leading the design and implementation of adaptive trials, has released ADDPLAN(R) DF 3.0, which incorporates complex statistical methodologies to prevent under and over-estimation of a therapeutic's maximum target dose (MTD) during Phase I dose escalation trials. Accurate estimation of MTD minimises safety and efficacy issues leading to late phase clinical trial failures and is of particular importance for oncology, which has one of the highest Phase III attrition rates among all major therapeutic classes.
RadNet Touches New 52-Week High - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon May 12, 9:05AM CDT
RadNet (RDNT) recorded an earnings surprise in 3 of its last 4 quarters, with an average beat of 133.96%.
Why ICON Public (ICLR) Could Beat Earnings Estimates Again - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri May 09, 7:37AM CDT
Recent estimates have been moving higher for ICON Public which is a great sign of a coming beat.
ICON to Webcast Analyst Day Meeting
Business Wire - Fri May 09, 5:01AM CDT
ICON plc, (NASDAQ:ICLR), a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced that it will provide a live webcast of its Analyst Day meeting which will take place on Wednesday, 14th May, 2014 in North Wales, Philadelphia, starting at 9:30 a.m. EST. The event will include presentations from members of ICON's executive team. It is expected that the presentations, followed by a question and answer session, will conclude by approximately 12:15 p.m. EST.
ICON announces completion of Aptiv Solutions acquisition
M2 - Fri May 09, 3:50AM CDT
ICON plc (Nasdaq:ICLR), a provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, announced on Thursday the completion of the acquisition of Aptiv Solutions, a designer and executor of adaptive clinical trials for pharmaceutical and biotech customers.
ICON Completes Acquisition of Aptiv Solutions
Business Wire - Thu May 08, 5:01AM CDT
ICON plc, (NASDAQ: ICLR), a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced that it has completed the previously announced acquisition of Aptiv Solutions.
ICON Down 11.7% Since SmarTrend Downtrend Call (ICLR)
Comtex SmarTrend(R) - Wed May 07, 5:08PM CDT
SmarTrend identified a Downtrend for ICON (NASDAQ:ICLR) on April 7th, 2014 at $43.58. In approximately 1 month, ICON has returned 11.67% as of today's recent price of $38.49.
Can ICON Public Limited Company (ICLR) Stock Continue to Grow Earnings? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed May 07, 7:50AM CDT
ICON Public has been witnessing a significant price rise in the past month with a positive momentum in the earnings estimate front
Global Pharmacovigilance Market 2013-2019 - New Opportunities in the $2 Billion Industry
M2 - Wed May 07, 3:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mzp99x/pharmacovigilance) has announced the addition of the "Pharmacovigilance Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019" report to their offering. The total market for global pharmacovigilance services is estimated to be USD 2,147.3 million in 2012 and is forecast to grow at a CAGR of 12.9% from 2013 to 2019 Some of the major players profiled in this report include PRA International Inc., Covance Inc., Synowledge LLC, OptumInsight Inc., iMedGlobal, TCS, iGATE Corporation, Cognizant Technology Solutions, Quintiles and others. Today, pharmacovigilance is considered as a continuous process of evaluation in most of the pharmaceutical companies to reduce the risks associated in bringing the new drug in to the market and to improve the safe usage of medicinal products. The proper rules and guidelines for implementation of drug safety monitoring programs has been formulated by various national and international regulatory authorities such as World Health Organization (WHO) and United States Food and Drugs Administration (USFDA). The global pharmacovigilance market has been segmented based on the type of clinical trials phases, type of service providers and by type of methods used in drug safety reporting. Based on the type of service providers, the market has been segmented in to in-house and contract outsourcing services. Among these, contract outsourcing services market accounts for the largest market share in 2012 and expected to continue the same till 2019 owing to the high cost involvement, growing regulatory concerns and requirement of highly qualified professionals for drug safety reporting. Based on type of clinical trials phases, the total market for pharmacovigilance services is categorized into pre-clinical studies, phase I, II, III and IV (post-marketing surveillance services). Among afore-mentioned services, the market for phase IV services accounts for the largest market share in 2012. Scope Clinical Trial Phases - Pre-Clinical Studies - Phase I - Phase II - Phase III - Phase IV - Post-Marketing Surveillance Service Providers - In-House - Contract Outsourcing Key Topics Covered: Chapter 1 Introduction Chapter 2 Executive Summary Chapter 3 Global Pharmacovigilance Market Dynamics Chapter 4 Global Pharmacovigilance Market, by Clinical Trial Phases Chapter 5 Global Pharmacovigilance Market, By Type of Methods Chapter 6 Global Pharmacovigilance Market, by Type of Service Providers Chapter 7 Global Pharmacovigilance Market, by Geography Chapter 8 Global Pharmacovigilance Market Share Analysis Chapter 9 Recommendations Chapter 10 Company Profiles - Accenture, Plc - Bristol-Myers Squibb - Clinquest Group B.V. - Cognizant Technology Solutions - Covance, Inc. - F. Hoffmann-La Roche Ltd. - GlaxoSmithKline (GSK) - iGATE Corporation - iMEDGlobal Corporation - inVentiv Health Inc. - ICON, Plc - Infosys - Johnson and Johnson - Novartis International AG - OptumInsight, Inc. - PRA International, Inc. - Parexel International Corporation - Pfizer, Inc. - Pharmaceutical Product Development, Inc. (PPD, Inc.) - Quantum Solutions India - Quintiles Transnational Corporation - Sanofi Aventis - Synowledge LLC - United BioSource Corporation - Wipro Limited For more information visit http://www.researchandmarkets.com/research/mz...ovigilance
Life Sciences BPO Market Report with Forecasts to 2019: Contract Research Organizations & Contract Manufacturing Organizations
M2 - Fri May 02, 4:28AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zvdqxl/life_sciences_bpo) has announced the addition of the "Life Sciences BPO Market Report with Forecasts to 2019: Contract Research Organizations & Contract Manufacturing Organizations" report to their offering. The major players of this market are CatalentPharma Solutions, PRA International, Covance, Quintiles, Parexel, DSM, Charles River Laboratories, Piramal Healthcare and BoehringerIngelheim. Economic burden, increased financial crisis and technological advances has compelled all pharmaceutical, biotechnology and life science companies to outsource their R&D activities and manufacturing processes in order to achieve their cost benefits and save time.In recent years, large number of life science companies has modified their traditional drug manufacturing operations with more focus now on their core R&D activities and manufacturing processes via outsourcing. Global Life Sciences BPO market includes Contract Manufacturing Organizations (CMOs), Contract Research Organizations (CROs) and others that compriseContract Sales Organization (CSO). The contract manufacturing organizations market is expected to see the highest growth rate during the forecast period and also accounted for the largest market share in the year 2012. This market holds immense growth owing to the rise in demand for generic drugs, increase in R&D investment by life sciences companies. In addition, a rise in the number of block buster drugs going off-patent and increased adoption of novel technologies are further boosting the growth of this market. The CMO market comprises contract API (Active Pharmaceutical Ingredients) manufacturing, contract FDF (Finished Dosage Formulations) manufacturing and packaging.Among these, contract FDF manufacturing segment is expected to have a healthy growth rate during the forecast period. The CRO market is also expected to display a healthy growth rate after CMO market. The CRO market comprises of various segments such as drug discovery, pre-clinical studies, clinical trial phases, medical writing, clinical data management, pharmacovigilance, regulatory services, site management, protocol development, monitoring and bio-statistics. Among these, clinical data management segment is expected to have a strong growth rate in coming years. This growth has been attributed to its high data complexities, high cost involvement and requirement of skilled & trained professionals. Scope Contract Research Organizations - Drug Discovery - Pre-Clinical - Clinical Trials - Medical Writing - Pharmacovigilance - Risk-Based Monitoring - Clinical Data Management - Biostatistics Contract Manufacturing Organizations Companies Mentioned - Accenture, Plc - Boehringer Ingelheim GmbH - Catalent Pharma Solutions, Inc. - Charles River Laboratories International, Inc. (CRL) - Cognizant Technology Solutions - Covance, Inc. - DSM - Fareva - ICON, Plc - Infosys - International Business Machines Corporation - Lonza Group - Pharmaceutical Product Development, Inc. (PPD, Inc.) - Parexel International Corporation - Patheon, Inc. - Piramal Healthcare - PRA International, Inc. - Quintiles Transnational Corporation - Wipro Limited For more information visit http://www.researchandmarkets.com/research/zv...iences_bpo
Charles River Beats on Earnings, Guidance Upped - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu May 01, 2:34PM CDT
Charles River Laboratories (CRL) reported first quarter 2014 earnings (excluding special items) of 82 cents per share, easily beating the Zacks Consensus Estimate of 74 cents and up from 69 cents in the year-ago quarter.
ICON Shares Down 12.8% Since SmarTrend's Sell Call (ICLR)
Comtex SmarTrend(R) - Wed Apr 30, 11:20AM CDT
SmarTrend identified a Downtrend for ICON (NASDAQ:ICLR) on April 7th, 2014 at $43.58. In approximately 3 weeks, ICON has returned 12.77% as of today's recent price of $38.01.
ICON Announces Appointment of Dr. Hugh Brady to Board of Directors
Business Wire - Wed Apr 30, 5:15AM CDT
ICON plc, (NASDAQ: ICLR), a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced the appointment of Dr. Hugh Brady as a non-executive director.
ICON Reports First Quarter 2014
Business Wire - Wed Apr 30, 5:00AM CDT
--Quarter 1 net revenue increased 10% year on year to $350 million.
Health Care Equities under Review -- Research on PerkinElmer, Quintiles Transnational Holdings, WuXi PharmaTech Cayman, and ICON
PR Newswire - Tue Apr 15, 11:54AM CDT
The trading session on Monday, April 14, 2014 ended on a higher note as the S&P 500 finished the session 0.82% higher at 1,830.61 and the NASDAQ Composite closed at 4,022.69, up 0.57%. The Dow Jones Industrial Average finished at 16,173.24, up 0.91%. During the session, all the ten sectors ended in positive. The S&P 500 Health Care Sector Index ended the day at 648.05, up 0.51%, whereas the same has declined 1.86% in the last three months. Investor-Edge has initiated coverage on the following equities: PerkinElmer Inc. (NYSE: PKI), Quintiles Transnational Holdings Inc. (NYSE: Q), WuXi PharmaTech Cayman Inc. (NYSE: WX) and ICON PLC (NASDAQ: ICLR). Free technical research on PKI, Q, WX and ICLR can be downloaded upon signing up at:
Quest Diagnostics Raised to Buy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 14, 4:32PM CDT
Adjusted earnings per share of Quest Diagnostic came in at $1.03, beating the Zacks Consensus Estimate of 94 cents by 9.6%, and exceeding the company's prior-year earnings by 2%.
Weakness Seen in WellCare Health Plans (WCG): Stock Falls 5.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Apr 14, 7:33AM CDT
WellCare Health Plans (WCG) fell nearly 6% in the last trading session amid huge volumes, continuing its recent volatile trend as it is currently trading within the volatile price range of last one month.
Product Launches, Acquisitions, Closed Offerings, Divestitures, and Financial Results - Analyst Notes on Dr. Reddy's, ICON, Endocyte, BioScrip, and DepoMed
PR Newswire - Mon Apr 07, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Dr. Reddy's Laboratories Ltd. (NYSE: RDY), ICON plc (NASDAQ: ICLR), Endocyte, Inc. (NASDAQ: ECYT), BioScrip Inc. (NASDAQ: BIOS), and DepoMed Inc. (NASDAQ: DEPO). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register